Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Sep 20, 2024
Episode
251
Soundcloud
Share
The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about this research and how the therapy will be used by clinicians.
Guest
Karen Reckamp
MD, MS
Clinical Professor in the Department of Medicine
Cedars-Sinai Medical Center, California, United States
William Nassib William
MD
National Leader of Thoracic Oncology
Oncolinicas
